GlassScriptPhysician profile
Dayyan Adoor
NPI 1346800588
$4,206.78
in general payments reported to CMS, 2019-2025
18 companies · $2,300 in 2025
The $2,300 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.09 · 2022: $372 · 2023: $508 · 2024: $1,014 · 2025: $2,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020 · Travel and Lodging: $1,703 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.72 |
| Travel and Lodging | $1,703.41 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,389.45 | 2025 | Farapulse, Accolade Sr |
| Olympus Corporation of The Americas | $589.15 | 2025 | Single Use Biliary Balloon Dilator |
| Abbvie INC. | $352.31 | 2022-2024 | Rinvoq, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $316.61 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.21 | 2022-2025 | Xifaxan, Plenvu |
| Medtronic, INC. | $209.31 | 2024 | Barrx |
| Gilead Sciences, INC. | $197.36 | 2022-2024 | Vemlidy, Livdelzi |
| Janssen Biotech, INC. | $184.41 | 2024 | Stelara, Tremfya |
| Intercept Pharmaceuticals, INC. | $154.84 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $122.62 | 2022-2024 | Dificid, Keytruda |
| Lilly USA, LLC | $99.87 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $98.64 | 2024 | Voquezna |
| Olympus America INC. | $87.02 | 2025 | Single Use Electrosurgical Knife Kd-655, Single Use Aspiration Needle Na-U200h, Endoclot Phs |
| Mallinckrodt Hospital Products INC. | $56.90 | 2023-2025 | Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.49 | 2023 | Spiriva Respimat |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $28.65 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $17.85 | 2024 | Iqirvo |
| Amgen INC. | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dayyan Adoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.